Akero Therapeutics
Stock Forecast, Prediction & Price Target
Akero Therapeutics Financial Estimates
Akero Therapeutics Revenue Estimates
Akero Therapeutics EBITDA Estimates
Akero Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $28.07M Low: $28.07M High: $28.07M avg. 0% | Avg: $58.02M Low: $58.02M High: $58.02M avg. 106.69% | Avg: $216.68M Low: $216.68M High: $216.68M avg. 273.43% |
Net Income
% change YoY
| $-100.73M N/A | $-108.91M -8.11% | $-151.75M -39.34% | Avg: $-283.69M Low: $-253.37M High: $-193.97M avg. -86.93% | Avg: $-306.48M Low: $-229.25M High: $-195.02M avg. -8.03% | Avg: $-146.97M Low: $-146.97M High: $-146.97M avg. 52.04% | Avg: $-14.04M Low: $-14.04M High: $-14.04M avg. 90.44% |
EBITDA
% change YoY
| $-100.88M N/A | $-111.29M -10.31% | $-148.63M -33.54% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$2.89 N/A | -$2.79 3.46% | -$2.89 -3.58% | Avg: -$4.34 Low: -$4.82 High: -$3.69 avg. -50.22% | Avg: -$4 Low: -$4.36 High: -$3.71 avg. 7.82% | Avg: -$2.8 Low: -$2.8 High: -$2.8 avg. 30.13% | Avg: -$0.27 Low: -$0.27 High: -$0.27 avg. 90.44% |
Operating Expenses
% change YoY
| $100.88M N/A | $115.15M 14.14% | $172.87M 50.11% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Akero Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 11.87% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -253.37M, average is -283.69M and high is -193.97M.
What is Akero Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 95.03% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Akero Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 19.54% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$4.82, average is -$4.34 and high is $-3.69.
What is the best performing analyst?
In the last twelve months analysts have been covering Akero Therapeutics stock. The most successful analyst is Edward Nash.